The role of Anti-PAD4, Anti-CarP, and Anti-RA33 antibodies combined with rheumatoid factor (RF) and anti-citrullinated protein antibodies (ACPA) in predicting abatacept response in rheumatoid arthritis
Main finding · Moderate or good EULAR responseResult — go to the resultAdjusted odds ratio 2.7Authors' conclusion
This study highlights the potential benefits of using a combined assessment of ACPA aPAD4 and aCarP in predicting effectiveness of ABT in RA.
Study context
- Population
- Consecutive abatacept-treated rheumatoid arthritis (RA) patients
- Participants
- 121 patients
- Exposure
- AAb positivity vs negativity
- Outcome
- Moderate or good EULAR response at 6 months and 3-year abatacept retention
- Follow-up
- 6 months; 3 years
Methodological detailsconsecutive patients, retrospective assessment of RF and ACPA status, multiple logistic regression, Cox regression, adjusted for confounders
- Consecutive patients
- Retrospective assessment of RF and ACPA status
- Multiple logistic regression
- Cox regression
- Adjusted for confounders
Main finding
Moderate or good EULAR response · 6 months
Adjusted odds ratio
2.7
p 0.026
As reported in the abstract
- Moderate or good EULAR response at 6 months, whole cohort
- 64.5%
Observational data: associations, not effects.
Further findings
| Outcome | Single or double positive | Triple negative | aHR | P value |
|---|---|---|---|---|
| 3-year abatacept retention · 3 yearsSingle or double positive vs Triple negative | 62.1% | 33.5% | 0.48 | p 0.022 |
- 3-year abatacept retention — Cumulative 3-year retention rate, whole cohort
- 56.6%
3-year abatacept retention
- ACPA, aPAD4, aCarP individually associated with higher 3-year retention; not statistically significant
EULAR response at 6 months by individual AAb (positive vs negative)
- RF positive vs negative
- 67% vs. 58%
- ACPA positive vs negative
- 68% vs. 57%
- aPAD4 positive vs negative
- 68% vs. 62%
- aCarP positive vs negative
- 72% vs. 62%
- Statistical significance not reached
AAb positivity prevalence
- RF
- 74.4%
- ACPA
- 69.4%
- aPAD4
- 43.8%
- aCarP
- 23.9%
- Anti-RA33 (aRA33)
- 14.9%
Original publication
The role of Anti-PAD4, Anti-CarP, and Anti-RA33 antibodies combined with RF and ACPA in predicting abatacept response in rheumatoid arthritis. Arthritis Res Ther. Published 15 January 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →